Literature DB >> 12842707

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

Emiko Komura1, Hédia Chagraoui, Véronique Mansat de Mas, Benoit Blanchet, Paulo de Sepulveda, Frédéric Larbret, Jérome Larghero, Michel Tulliez, Najet Debili, William Vainchenker, Stéphane Giraudier.   

Abstract

Spontaneous growth of megakaryocyte progenitors is one of the biologic hallmarks of idiopathic myelofibrosis (IMF). The molecular mechanisms underlying this hypersensitivity to cytokines are poorly understood. Using a differential display approach, we previously observed FK506 binding protein 51 (FKBP51) overexpression in pathologic megakaryocytes from IMF. Using an FKBP51-overexpressing cell line, we found sustained STAT5 activation associated with JAK2 phosphorylation. We subsequently tested whether this transcription factor was activated in patient samples. We detected a STAT5 nuclear translocation and activation in spontaneously grown megakaryocytes and in circulating CD34(+) cells from the majority of patients studied. The biologic role of this JAK/STAT pathway activation was demonstrated by inhibiting both the anti-apoptotic phenotype mediated by FKBP51 overexpression in UT7 cells and the spontaneous megakaryocytic growth by addition in culture of the JAK2 inhibitor AG490 or overexpression of a STAT5b dominant negative or SOCS-1. These results demonstrate that a constitutive STAT5 activation in IMF is indispensable for spontaneous growth of megakaryocytes. They also suggest that FKBP51 overexpression could be involved in STAT5 activation in IMF cells and in subsequent abnormal growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842707     DOI: 10.1016/s0301-472x(03)00085-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

Review 1.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

2.  Absence of JAK2 V617F mutation in thalassemia intermedia patients.

Authors:  Ali Taher; Dina Shammaa; Ali Bazarbachi; Doha Itani; Ghazi Zaatari; Layal Greige; Zaher K Otrock; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

3.  Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.

Authors:  Chien-Yu Lin; Cheng-Mao Ho; Gevorg Tamamyan; Shu-Fen Yang; Ching-Tien Peng; Jan-Gowth Chang
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

4.  Hsp90-binding immunophilin FKBP51 forms complexes with hTERT enhancing telomerase activity.

Authors:  Mariana Lagadari; Nadia R Zgajnar; Luciana I Gallo; Mario D Galigniana
Journal:  Mol Oncol       Date:  2016-05-17       Impact factor: 6.603

Review 5.  The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.

Authors:  Martha Wadleigh; D Gary Gilliland
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

6.  Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

Authors:  Daisuke Okamura; Akira Matsuda; Maho Ishikawa; Tomoya Maeda; Ken Tanae; Mika Kohri; Naoki Takahashi; Nobutaka Kawai; Norio Asou; Masami Bessho
Journal:  Leuk Res Rep       Date:  2014-04-16

Review 7.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

Review 8.  The emerging role of large immunophilin FK506 binding protein 51 in cancer.

Authors:  S Romano; A Sorrentino; A L Di Pace; G Nappo; C Mercogliano; M F Romano
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 9.  STAT signaling in the pathogenesis and treatment of myeloid malignancies.

Authors:  Michal Bar-Natan; Erik A Nelson; Michael Xiang; David A Frank
Journal:  JAKSTAT       Date:  2012-04-01

10.  Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation.

Authors:  Dominique Bluteau; Alessandra Balduini; Nathalie Balayn; Manuela Currao; Paquita Nurden; Caroline Deswarte; Guy Leverger; Patrizia Noris; Silverio Perrotta; Eric Solary; William Vainchenker; Najet Debili; Remi Favier; Hana Raslova
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.